BioCentury | May 4, 2019
Product Development

How the amyloid hypothesis holds its grip

By now, two things are clear about the amyloid hypothesis of Alzheimer’s disease: one is that the amyloid peptide is somehow involved; the other is that it’s a terrible target. β amyloid has had an...
BioCentury | May 4, 2019
Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
BC Week In Review | Nov 9, 2018
Clinical News

Lilly drops BACE inhibitors for Alzheimer’s

Eli Lilly and Co. (NYSE:LLY) discontinued the combination arm evaluating anti-β-amyloid mAb LY3002813 plus BACE inhibitor LY3202626 in the Phase II TRAILBLAZER-ALZ trial to treat Alzheimer's disease. Spokesperson Nicole Herbert told BioCentury that Lilly has...
BC Week In Review | Jun 15, 2018
Clinical News

Lilly, AZ stop Phase III Alzheimer's trials of BACE inhibitor

Eli Lilly and Co. (NYSE:LLY) and AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued a pair of Phase III trials evaluating once-daily oral lanabecestat (AZD3293, LY3314814) to treat Alzheimer's disease after an IDMC analysis concluded that both trials...
BC Extra | Jun 12, 2018
Clinical News

Lilly, AZ stop Phase III Alzheimer's trials of BACE inhibitor

Eli Lilly and Co. (NYSE:LLY) and AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued a pair of Phase III trials evaluating once-daily oral lanabecestat (AZD3293, LY3314814) to treat Alzheimer's disease after an IDMC analysis concluded that both trials...
BC Innovations | May 31, 2018
Product R&D

Lilly’s new leaf

As Daniel Skovronsky takes the helm of Eli Lilly and Co.’s R&D business, his goal is to shake the pharma’s reputation as a fast-follower and instead advance first-in-class therapeutics with large effect sizes. To get...
BioCentury | Mar 30, 2015
Product Development

Ready for PRIME time

If interim data on cognition that Biogen Inc. reported for aducanumab in Alzheimer's disease hold up, the risk of jumping directly from Phase Ib to Phase III testing will be more than worth it. The...
Items per page:
1 - 7 of 7